Somatic Mosaicism in Twins Discordant for Childhood Cancer

Description

Somatic mosaicism in cancer associated genes is one potential explanation for discordance in childhood cancer that has not been fully explored to date. This pilot study will focus on twins with central nervous system (CNS) tumors who are identified through the Children's Oncology Group's Project: EveryChild (PEC) registry or volunteer.

Conditions

Pediatric Central Nervous System Tumor, Central Nervous System Tumor, Discordant Twin, Somatic Mutation

Talk to us

Study Overview

On this page

Study Details

Study overview

Somatic mosaicism in cancer associated genes is one potential explanation for discordance in childhood cancer that has not been fully explored to date. This pilot study will focus on twins with central nervous system (CNS) tumors who are identified through the Children's Oncology Group's Project: EveryChild (PEC) registry or volunteer.

Somatic Mosaicism in Twins Discordant for Childhood Cancer: a Pilot Study

Somatic Mosaicism in Twins Discordant for Childhood Cancer

Condition
Pediatric Central Nervous System Tumor
Intervention / Treatment

-

Contacts and Locations

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55455

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Newly diagnosed patient with CNS tumor or have recurrent disease and enrolled on APEC14B1.
  • * Patient must have same sex twin. Note: (history of) treatment on a COG therapeutic trial is not required.
  • * Patients must be diagnosed at \< 19 years of age at the time of diagnosis.
  • * A family is eligible to participate if the twin with the CNS tumor is deceased but has a blood sample banked through APEC14B1.
  • * All patients and/or their parents or legal guardians must provide informed consent. Assent will be obtained for participants between the ages of 8-17 years.
  • * All institutional, FDA, and NCI requirements for human studies must be met.

Ages Eligible for Study

to 18 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Oncology Group,

Jenny Poynter, PhD, STUDY_CHAIR, University of Minnesota

Study Record Dates

2025-12-31